Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Recruiting
Observational Study
Coronary Artery Disease
Antiplatelet Therapy
Minimally Invasive Coronary Revascularization Surgery
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- Cardiocentro Ticino · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.
The study compares patients receiving cangrelor during surgery to patients who had…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria for the historical control arm:
* Age ≥18 years old
* CABG with IMA-LAD graft in MIDCAB technique
Inclusion criteria for the prospective arm:
* Age ≥18 years old
* CABG with IMA-LAD graft in MIDCAB technique
* Signed informed consent
Exclusion criteria for the historical contr…
Contacts